<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>AIM: Advanced research has radically changed both diagnosis and treatment of <z:mp ids='MP_0002055'>diabetes</z:mp> during last three decades; a number of classes of oral <z:chebi fb="0" ids="35526">antidiabetic</z:chebi> agents are currently available for better glycemic control </plain></SENT>
<SENT sid="1" pm="."><plain>Present study aims to evaluate the effect of <z:chebi fb="0" ids="6801">metformin</z:chebi> on different stress and inflammatory parameters in diabetic subjects </plain></SENT>
<SENT sid="2" pm="."><plain>METHODS: 208 type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> patients were randomly assigned for <z:chebi fb="0" ids="6801">metformin</z:chebi> and placebo </plain></SENT>
<SENT sid="3" pm="."><plain>RESULTS: Reactive oxygen species generation, advanced oxidation protein products (179.65±13.6, 120.65±10.5 μmol/l) and pentosidine (107±10.4, 78±7.6 pmol/ml) were found to be reduced by <z:chebi fb="0" ids="6801">metformin</z:chebi> treatment compared to placebo </plain></SENT>
<SENT sid="4" pm="."><plain>On the other hand <z:chebi fb="0" ids="6801">metformin</z:chebi> administration enhanced total <z:chebi fb="0" ids="29256">thiol</z:chebi> and nitric <z:chebi fb="177" ids="25741,29356">oxide</z:chebi> level (p&lt;0.05) </plain></SENT>
<SENT sid="5" pm="."><plain>But nutrient level (Mg(+2), Ca(+2)) in plasma was not altered by the treatment </plain></SENT>
<SENT sid="6" pm="."><plain>Significant restoration of C reactive protein (p&lt;0.05) was noticed after <z:chebi fb="0" ids="6801">metformin</z:chebi> therapy </plain></SENT>
<SENT sid="7" pm="."><plain><z:chebi fb="0" ids="6801">Metformin</z:chebi> administration also improved Na(+)K(+)ATPase activity (0.28±0.08, 0.41±0.07 μmol <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">Pi</z:e>/mg/h) in erythrocyte membrane </plain></SENT>
<SENT sid="8" pm="."><plain>CONCLUSIONS: This study explores that <z:chebi fb="0" ids="6801">metformin</z:chebi> treatment restores the <z:chebi fb="11" ids="22586">antioxidant</z:chebi> status, enzymatic activity and inflammatory parameters in type 2 diabetic patients </plain></SENT>
<SENT sid="9" pm="."><plain><z:chebi fb="0" ids="6801">Metformin</z:chebi> therapy improves the status of oxidative and nitrosative stress altered in type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> </plain></SENT>
<SENT sid="10" pm="."><plain>This study unfolds the cardio protective role of <z:chebi fb="0" ids="6801">metformin</z:chebi> as an oral <z:chebi fb="0" ids="35526">hypoglycemic agent</z:chebi> </plain></SENT>
</text></document>